|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Approach to the endoscopic resection of duodenal lesions显示文摘Duodenal polyps or lesions are uncommonly found on upper endoscopy. Duodenal lesions can be categorized as subepithelial or mucosally-based, and the type of lesion often dictates the work-up and possible therapeutic options. Subepithelial lesions that can arise in the duodenum include lipomas, gastrointestinal stromal tumors, and carcinoids. Endoscopic ultrasonography with fine needle aspiration is useful in the characterization and diagnosis of subepithelial lesions. Duodenal gastrointestinal stromal tumors and large or multifocal carcinoids are best managed by surgical resection. Brunner's gland tumors, solitary Peutz-Jeghers polyps, and non-ampullary and ampullary adenomas are mucosally-based duodenal lesions, which can require removal and are typically amenable to endoscopic resection. Several anatomic characteristics of the duodenum make endoscopic resection of duodenal lesions challenging. However, advanced endoscopic techniques exist that enable the resection of large mucosally-based duodenal lesions. Endoscopic papillectomy is not without risk, but this procedure can effectively resect ampullary adenomas and allows patients to avoid surgery, which typically involves pancreaticoduodenectomy. Endoscopic mucosal resection and its variations(such as cap-assisted, cap-band-assisted, and underwater techniques) enable the safe and effective resection of most duodenal adenomas. Endoscopic submucosal dissection is possible but very difficult to safely perform in the duodenum. | Jonathan P Gaspar Edward B Stelow Andrew Y Wang | 2016 | World Journal of Gastroenterology2016，22，2： | 17 |
| 2 | Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events显示文摘AIM: To compare thromboembolism rates between hospitalized patients with a diagnosis of ulcerative colitis and other hospitalized patients at high risk for thromboembolism. To compare thromboembolism rates between patients with ulcerative colitis undergoing a colorectal operation and other patients undergoing colorectal operations. METHODS: Data from the National Hospital Discharge Survey was used to compare thromboembolism rates between (1) hospitalized patients with a discharge diagnosis of ulcerative colitis and those with diverticulitis or acute respiratory failure, and (2) hospitalized patients with a discharge diagnosis of ulcerative colitis who underwent colectomy and those with diverticulitis or colorectal cancer who underwent colorectal operations. RESULTS: Patients diagnosed with ulcerative colitis had similar or higher rates of combined venous thromboembolism (2.03%) than their counterparts with diverticulitis (0.76%) or respiratory failure (1.99%), despite the overall greater prevalence of thromboembolic risk factors in the latter groups. Discharged patients with colitis that were treated surgically did not have signifi cantly different rates of venous or arterial thromboembolism than those with surgery for diverticulitis or colorectal cancer.CONCLUSION: Patients with ulcerative colitis who do not undergo an operation during their hospitalization have similar or higher rates of thromboembolism than other medical patients who are considered to be high risk for thromboembolism. | Jennifer Y Wang Jonathan P Terdiman Eric Vittinghoff Tracy Minichiello Madhulika G Varma | 2009 | World Journal of Gastroenterology2009，15，8： | 8 |
| 3 | Costimulation of resting B lymphocytes alters the IL-4-activated IRS2 signaling pathway in a STAT6 independent manner: implications for cell survival and proliferation显示文摘IL-4 is an important B cell survival and growth factor. IL-4 induced the tyrosine phosphorylation of IRS2 in resting B lymphocytes and in LPS- or CD40L-activated blasts. Phosphorylated IRS2 coprecipitated with the p85 subunit of PI 3’ kinase in both resting and activated cells. By contrast, association of phosphorylated IRS2 with GRB2 was not detected in resting B cells after IL-4 treatment although both proteins were expressed. However, IL-4 induced association of IRS2 with GRB2 in B cell blasts. The pattern of IL-4- induced recruitment of p85 and GRB2 to IRS2 observed in B cells derived from STAT6 null mice was identical to that observed for normal mice. While IL-4 alone does not induce activation of MEK, a MEKI inhibitor suppressed the IL-4-induced proliferative response of LPS-activated B cell blasts. These results demonstrate that costimulation of splenic B cells alters IL-4-induced signal transduction independent of STAT6 leading to proliferation. Furthermore, proliferation induced by IL-4 in LPS-activated blasts is dependent upon the MAP kinase pathway. | ZAMORANO JOSE,Unidad de Investigacion, Hospital San Pedro de Alcantara, Avda Millan Astray, 10003 Caceres ANN E KELLY, JONATHAN AUSTRIAN, HELEN Y WANG, ACHSAH D KEEGAN (Department of Immunology, Jerome Holland Labs, American Red Cross, Rockville, MD, USA | 2001 | Cell Research2001，11，1： | 4 |
| 4 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 3 |
| 5 | Strategies to tackle the challenges of external beam radiotherapy for liver tumors显示文摘Primary and metastatic liver cancer is an increasingly common and difficult to control disease entity.Radiation offers a non-invasive treatment alternative for these patients who often have few options and a poor prognosis.However,the anatomy and aggressiveness of liver cancer poses significant challenges such as accurate localization at simulation and treatment,management of motion and appropriate selection of dose regimen.This article aims to review the options available and provide information for the practical implementation and/or improvement of liver cancer radiation programs within the context of stereotactic body radiotherapy and image-guided radiotherapy guidelines.Specific patient inclusion and exclusion criteria are presented given the significant toxicity found in certain sub-populations treated with radiation.Indeed,certain sub-populations,such as those with tumor thrombosis or those with larger lesions treated with transarterial chemoembolization,have been shown to have significant improvements in outcome with the addition of radiation and merit special consideration.Implementing a liver radiation programrequires three primary challenges to be addressed:(1) immobilization and motion management;(2) localization;and(3) dose regimen and constraint selection.Strategies to deal with motion include simple internal target volume(ITV) expansions,non-gated ITV reduction strategies,breath hold methods,and surrogate marker methods to enable gating or tracking.Localization of the tumor and organs-at-risk are addressed using contrast infusion techniques to take advantage of different normal liver and cancer vascular anatomy,imaging modalities,and margin management.Finally,a dose response has been demonstrated and dose regimens appear to be converging.A more uniform approach to treatment in terms of technique,dose selection and patient selection will allow us to study liver radiation in larger and,hopefully,multicenter randomized studies. | Michael I Lock Jonathan Klein Hans T Chung Joseph M Herman Edward Y Kim William Small Nina A Mayr Simon S Lo | 2017 | World Journal of Hepatology2017，9，14： | 2 |
| 6 | Matching algorithms for three-stagebufferless Clos network switches 显示文摘 | H Jonathan Chao Zhigang Jing Soung Y Liew | 2003 | IEEE Communication Magazine2003，41，10： | 1 |
| 7 | Outlook for cellulase improvement: Screening and selection strategies 显示文摘 | Zhang Y H Michael E Himmel Jonathan R Mielenz | 2006 | Biotechnology Advances2006，24，： | 1 |
| 8 | AtERF14, a member of the ERF family of transcription factors, plays anonredundant role in plant defense 显示文摘 | Luis onate-Sanchez Jonathan P A Jodi Y | 2007 | Plant Physiology2007，143，1： | 1 |
| 9 | Outlook for cellulase improvement: Screening and selection strategies显示文摘 | Zhang Y H Himmel Michael E Mielenz Jonathan R | 2006 | Biotechnology Advance2006，24，5： | 1 |
| 10 | Prevention of fat - induced insulin resistance by salicylate 显示文摘 | Jason K Kim Y J Jonathan J | 2005 | J Clin Invest2005，108，： | 1 |
| 11 | Outlook for ellulase improvement: Screening and selection strategies 显示文摘 | Zhang Y H P Michael E H Jonathan R M | 2006 | Biotechnology Advances2006，24，： | 1 |
| 12 | Side resistance of large diameter bored piles socketed into decomposed rock显示文摘 | Charles W W N Terence L Y Y Jonathan H M L | 2001 | Journal of Geotechnical and Geoenvironmental Engineering ASCE2001，127，8： | 1 |
| 13 | Differential responses of normal,premalignant,and malignant human bronchial epithelial cells to receptor-selective retinoids显示文摘 | Shi-Yong S Jonathan M K Ping Y | 1999 | Clin Cancer Res1999，5，： | 1 |
| 14 | Accelerated evolution and coevolution drove the evolutionary history of AGPase sub-units during angiosperm radiation显示文摘 | JONATHAN C JULIEN Y D CATHERINE D | | 0，，04： | 1 |
| 15 | AtERF14, a member of the ERF family of transcription factors, plays a nonre- dundant role in plant defense显示文摘 | ONATE-SANCHEZ L Jonathan P A Jodi Y | 2007 | Plant Physiology2007，143，1： | 1 |
| 16 | Instability sub harmonics and chaos in power electronic systems 显示文摘 | JONATHAN H B DEANE Y DAVID C | 1990 | Transaction on Power Electronics1990，5，3： | 1 |
| 17 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial显示文摘 | Paul Y Kwo Eric J Lawitz Jonathan McCone Eugene R Schiff John M Vierling David Pound Mitchell N Davis Joseph S Galati Stuart C Gordon Natarajan Ravendhran Lorenzo Rossaro Frank H Anderson Ira M Jacobson Raymond Rubin Kenneth Koury Lisa D Pedicone Clifford | 2010 | The Lancet2010，，9742： | 1 |
| 18 | Minireview class II transaetivator: mastering the art of major histocompatibility complex expression 显示文摘 | Jonathan A Harton Y Jenny P et ol | 2000 | Mol Cell Biol2000，20，17： | 1 |
| 19 | Mutational analysis of the complement receptor type 2 (CR2/CD21) C3d interaction reveals a putative charged SCR1 binding site for C3d显示文摘 | Jonathan P H Kendra A Y Joel M G | 2005 | J Mol Biol2005，346，： | 1 |
| 20 | Matching Algorithms for Three - stage Bufferless Clos Network Switches显示文摘 | Jonathan H Chao Jing Zhigang Soung Y Liew | 2003 | IEEE Communications Magazine2003，41，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员